×

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $50,000 From Investment in MiMedx Group, Inc. to Contact Brower Piven Before the November 8, 2013 Lead Plaintiff Deadline -- MDXG

STEVENSON, Md., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of MiMedx Group, Inc. ("MiMedx" or the "Company") (Nasdaq:MDXG) common stock during the period between March 15, 2013 and September 4, 2013, inclusive (the "Class Period").

If you have suffered a net loss from investment in MiMedx Group, Inc. common stock purchased on or after March 15, 2013, and held through the revelation of negative information on September 4, 2013, as described below, at no cost to you, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than November 8, 2013 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company stock during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period details about whether its AmnioFix product required approval by the U.S. Food and Drug Administration ("FDA") to be manufactured and marketed. According to the complaint, following September 4, 2013 news reports that the FDA had posted a letter on its website asserting that MiMedx's Surgical Biologics unit had violated the Public Health Service Act because its products required FDA approval, the value of MiMedx shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven Brower Piven, A Professional Corporation Stevenson, Maryland 410/415-6616 hoffman@browerpiven.comSource: Brower Piven, A Professional Corporation